Company intelligence / Profile preview

DAS Therapeutics

Boston, Massachusetts, United Statesdastherapeutics.com ↗

Ownership: Private
Development stage: Phase 2

Overview

DAS Therapeutics is conducting a Phase II clinical trial for its lead program, DAS-001, a fixed-dose combination of pyridostigmine and ondansetron. The trial aims to evaluate whether the addition of ondansetron can mitigate the gastrointestinal side effects commonly associated with pyridostigmine in patients with myasthenia gravis[2].

Therapeutic areas: Neurology
Modalities: Small moleculeCombination therapy (fixed-dose combination tablet)
Industry: Biotech

Drug pipeline

1 asset

pyridostigmine + antagonist

Phase 2

Indications: Myasthenia gravis

Partnerships

Collaboration with Dr. Henry Kaminski at George Washington University School of Medicine and Health Sciences for clinical research in myasthenia gravis

Beyond the preview

Go deeper on DAS Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DAS Therapeutics.

Explore the full profile